Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
AKT protein kinase inhibitor MK 2206, 5 mg  

AKT protein kinase inhibitor MK 2206, 5 mg

8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride

MK 2206 is an allosteric Akt inhibitor

More details

PKI-MK2206-005

Availability: within 3 days

165,00 €

Background: MK 2206 is an orally potent and highly selective non-ATP competitive allosteric Akt inhibitor that has nanomolar IC50 values (Akt1: 8 nM, AKT2:12 nM, AKT3: 65 nM) and broad preclinical anti-tumor activities.MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473

Chemical formula: C25H21N5O.2HCl
Molecular weight: 480.39 g/mol
Purity: >99%
Solubility: Soluble in water and DMSO
Appearance: White solid
CAS Number: 1032350-13-2

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers. 

References

H Hirai et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Mol. Cancer Ther. 2010, 9(7), 1956-1967.

AW Tolcher et al. A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). J. Clin. Oncol. 27:15s, 2009 (suppl; abstr 3503).

R Liu et al. The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway. J. Clin. Endocrinol. Metab. 2011, 96(4), E577-E585.

Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.